 |
|
|
||||||||||||||
 |
|
|
Tethys is dedicated to the discovery of novel multi-biomarker assays that identify individuals at highest risk for devastating diseases, such as diabetes. The goal of the Company is to provide new clinical practice tools that will help physicians and patients delay or prevent cardiometabolic disease and events.
We realize that our efforts will be enhanced by joining with strategic partners with shared interests in the cardiometabolic therapeutic arena and with a commitment to bettering the lives of individuals at risk for these diseases.
Tethys seeks partnerships with companies and organizations with aligned business objectives, shared customer base, synergistic and complementary capabilities and a willingness to engage in collaborative partnerships that can extend our respective corporate reaches.
Please send inquiries to partners@tethysbio.com
All information submitted is governed by our Privacy Policy.
Jul 22, 2010
Tethys Raises $33 Million
Tethys Bioscience, Inc., announced today that the company has recently raised $33 million, comprising $23 million of venture financing and a $10 million working capital loan.
Jul 14, 2010
Diabetes Risk, on a Scale of 1 to 10
A new test is transforming the way some doctors diagnose and treat their patients.
(Technology Review)
Jul 1, 2010
PreDx® featured on CBS Interactive's Smartplanet
CBS Interactive smartplanet video segment focuses on the impact of the PreDx® Diabetes Risk Score on the physician and patient.
Jun 24, 2010
Tethys Announces Issuance of Key Patent Relating to PreDx™ Diabetes Risk Score Test
United States Patent and Trademark Office grants patent to Tethys. The patent is directed to the company's groundbreaking PreDx™ Diabetes Risk Score (DRS) test and relates to proprietary methods for assessing the risk of developing a diabetic condition.
Nov 9, 2009
Tethys Bioscience Raises $25 Million in Series D Financing
The financing round is led by aeris Capital with George Rehm taking a seat on the Tethys board.
Oct 20, 2009
Gazing into the Future
(Journal of Life Sciences, Fall 2009)